Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: A two-year follow-up study

European Journal of Neurology

Volumn 17, Issue 3, 2010, Pages 470-478

  Garcia Montojo, M ^a   Dominguez Mozo, M I ^a   De Las Heras, V ^a   Bartolome, M ^a   Garcia Martinez, A ^a   Arroyo, R ^a   Alvarez Lafuente, R ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

CPE; Interferon beta; MMP 9; Multiple sclerosis; MxA; Neutralizing antibodies; TIMP 1

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; GELATINASE B; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CYTOPATHOGENIC EFFECT; DISEASE COURSE; DRUG BIOAVAILABILITY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECURRENT DISEASE;

EID: 77649104721     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02890.x     Document Type: Article

References (33)

1. PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001 56 : 1628.
2. Frank JA, Richert N, Bash C, et al. Interferon-beta-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb+ patients. Neurology 2004 62 : 719 725.
3. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000 48 : 706 712.
4. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002 59 : 1496 1506.
5. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998 50 : 1266 1272.
6. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005 65 : 48 55.
7. Hartung HP, Polman C, Bertolotto A, et al. Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. J Neurol 2007 254 : 827 837.
8. Kieseier BC, Seifert T, Giovannoni G, Hartung HP. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 1999 53 : 20 25.
9. Waubant E, Goodkin DE, Gee L, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999 53 : 1397 1401.
10. Gilli F, Bertolotto A, Sala A, et al. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 2004 127 : 259 268.
11. Medeiros M, Sharma VK, Ding R, et al. Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater. J Immunol Methods 2003 279 : 135 142.
12. Jordan RC, Abeo-Ong M, Shiboski CH, et al. Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res 2004 10 : 6460 6465.
13. Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003 61 : S24 S26.
14. Bertolotto A, Sala A, Malucchi S, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 2004 75 : 1294 1299.
15. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986 119 : 558 573.
16. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004 251 (Suppl. 2 II4 II9.
17. Noronha A. Neutralizing antibodies to interferon. Neurology 2007 68 : S16 S22.
18. WHO Expert Committee on Biological Standardization. Thirty-fifth report. World Health Organ Tech Rep Ser 1985 725 : 1 140.
19. The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996 47 : 889 894.
20. Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Neurology 2003 61 : S13 S17.
21. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 43 : 655 661.
22. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 359 : 1453 1460.
23. Polman CH, Kappos L, Petkau J, Thompson A. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2003 74 : 1162 1163.
24. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005 65 : 40 47.
25. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996 39 : 285 294.
26. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 352 : 1491 1497.
27. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004 63 : 1788 1795. (Pubitemid 39532370)
28. Leppert D, Lindberg RL, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 2001 36 : 249 257.
29. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994 94 : 2177 2182.
30. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996 40 : 846 852.
31. Proost P, Van DJ, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993 192 : 1175 1181.
32. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998 121 (Pt 12 2327 2334.
33. Waubant E, Goodkin D, Bostrom A, et al. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003 60 : 52 57.